BenchSci vs Insilico Medicine
A side-by-side comparison of BenchSci and Insilico Medicine, two Science tools, drawn from Ignaite's continuously-verified listings.
Compared from listings verified as of
Insilico Medicine
ScienceGenerative AI drug discovery — the end-to-end Pharma.ai suite.
View Insilico MedicineAt a glance
| Attribute | BenchSci | Insilico Medicine |
|---|---|---|
| Category | Science | Science |
| Pricing | PAID | PAID |
| License | Proprietary | Proprietary |
| Deployment | Cloud | Cloud |
| Platforms (differs) | Web | Web, API |
| Model support (differs) | Multi-model | Self-contained (on-device) |
| Vendor (differs) | BenchSci | Insilico Medicine |
The honest brief
BenchSci
Built on a decade-curated Biological Evidence Knowledge Graph of 100M+ papers and figures, not a general LLM bolted onto literature search.
- Grounds answers in curated biomedical evidence
- Reduces unnecessary preclinical experiments
- Integrates a customer's proprietary internal data
- Adopted by top-10 pharma companies
- Enterprise-only; pricing not public
- Narrowly scoped to preclinical R&D
- Requires onboarding with a dedicated team
Insilico Medicine
Sells its full discovery pipeline as licensed software — pharma can run PandaOmics and Chemistry42 directly, not just via a partner-only program.
- End-to-end Pharma.ai software suite
- Used by most of the top-20 pharma
- First AI-designed drug into Phase 2
- $2.75B Eli Lilly partnership
- Enterprise-only, opaque pricing
- Built for pharma R&D, not general users
- No approved drug yet
- Heavy domain expertise required